Necroptosis-related lncRNA biomarkers for colon cancer prognosis and the associations with the immune landscape.

Tao Wang,Shaohua Xu,Qian Wang,Shanshan Xiao,
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e15525
IF: 45.3
2022-06-01
Journal of Clinical Oncology
Abstract:e15525 Background: Necroptosis is a regulated caspases-independent cell death involved in colon cancer development and antitumor activity. lncRNAs are widely considered as biomarkers in various diseases. In this study, we identified prognosis biomarkers using necroptosis-related lncRNAs, and predict immunotherapeutic responses for colon cancer. Methods: A total of 453 colon cancer (CRC) patients (480 normal and 41 tumor samples) were enrolled in this study. The RNA expression dataset were obtained from The Cancer Genome Atlas (TCGA-COAD). They were randomly grouped as training set and validation set(7:3 ratio). Necroptosis-related lncRNAs were identified using Pearson’s correlation analysis with 67 necroptosis-related genes previously reported. Stepwise Cox regression and LASSO algorithm were performed to construct the prognostic risk score model. The overall survival (OS) difference between the high- and low-risk groups(cutoff using median risk score) was compared using Kaplan-Meier statistics. Furthermore, we evaluated the associations between the identified lncRNAs and the immune-related phenotypes including tumor micro-environment (TME) scores calculated by ESTIMATE, immune cell infiltration estimated by CIBERSORT, chemotherapeutics sensitivity predicted by pRRophetic and immune checkpoint expression,etc. Results: A total of 1926 necroptosis-related lncRNAs were identified and four lncRNAs (LINC02753, AC073283, AC010973, AP003555) were found to be correlated with 10 differential expressed necroptosis-related genes. The identified four lncRNAs were used to construct the prognostic model. The identified biomarkers was found to significantly correlate with worse prognosis in TCGA cohort (Train set: HR = 4.65, 95%CI = 2.42-8.93, P < 0.001; Validation set: HR = 3.06, 95%CI = 1.32-7.12, P = 0.006; Whole set: HR = 4.04, 95%CI = 2.41-6.76, P < 0.001) and was found to be independent to clinicopathological parameters. In addition, the lower TME scores suggested the lower infiltration of non-tumor cells in high-risk group and eight drugs were predicted to be more effective in high-risk group (i.e., PAC-1, AS601245). Further immune-related analysis revealed that the infiltrating immune cells including B cells, CD4 T cells, resting NK cells, M1 macrophages, monocytes, were all significantly different between the two groups. Moreover, TNF superfamily members (i.e., TNFSF14/15/25) were found to be substantially increased in high-risk group, which was considered as a type of important immune checkpoint molecule and participates in the initiation and regulation of necroptosis. Conclusions: The identified 4-lncRNA signature based on necroptosis showed potential prognosis value in CRC patients. The results can also help to guide immunotherapy and clinical research with TNFSF inhibitors for colon cancer patients with further experimental and clinical validation.
oncology
What problem does this paper attempt to address?